NCT03741829 is a clinical trial in Small Cell Lung Cancer, sponsored by Wake Forest University Health Sciences.

Who is sponsoring NCT03741829?

NCT03741829 is sponsored by Wake Forest University Health Sciences.

What condition does NCT03741829 study?

NCT03741829 studies Small Cell Lung Cancer.

Is NCT03741829 still recruiting?

NCT03741829 is currently completed. Last updated 5 February 2020.

Last reviewed 2020-02-05 · How we verify

NCT03741829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TS Overexpression in SCLC: Mechanism and Therapeutic Targeting

Completed Last updated 5 February 2020

What this trial tests

trial in Small Cell Lung Cancer in 12 participants. Completed in 3 January 2020.

Timeline

14 June 2017

Primary endpoint
3 January 2020

3 January 2020

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12
Start date	14 June 2017
Primary completion	3 January 2020
Estimated completion	3 January 2020
Sites	1 location across United States

Conditions studied

Small Cell Lung Cancer — all drugs for Small Cell Lung Cancer →

Sponsor

Wake Forest University Health Sciences

Who can join

18 and older, any sex, with Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to determine the amount of a protein named thymidine synthase that is being made by cancer and to develop laboratory models called PDX (patient derived xenografts) to learn more about SCLC (small cell lung cancer) and to begin testing new treatments.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy.
Frydrychowicz M, Kuszel Ł, Dworacki G, Budna-Tukan J. · · 2023 · cited 24× · PMID 36821071 · DOI 10.1007/s13353-023-00750-2
Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs.
Fàbrega C, Clua A, Eritja R, Aviñó A. · · 2023 · cited 5× · PMID 34844535 · DOI 10.2174/0929867328666211129124039

Verify or expand the search:

Other recruiting trials for Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
NCT07296809 — SKB500 Combinations in Patients With Small Cell Lung Cancer · Phase 2 · recruiting
NCT07155200 — Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial) · Phase 1, PHASE2 · recruiting
NCT06922539 — ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer · Phase 1 · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03741829 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 5 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03741829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing